{
  "ticker": "LLY",
  "target_date": "2025-08-13",
  "actual_date": "2025-08-13",
  "collected_at": "2025-12-08T12:08:16.500751",
  "price": {
    "open": 648.02,
    "high": 659.33,
    "low": 642.14,
    "close": 658.0759887695312,
    "volume": 6310000,
    "change_1d_pct": 3.29,
    "change_7d_pct": -14.11,
    "change_30d_pct": -14.87
  },
  "technicals": {
    "rsi_14": 24.75,
    "sma_20": 737.56,
    "sma_50": 763.88,
    "macd": -34.151,
    "macd_signal": -19.882,
    "macd_histogram": -14.269,
    "bb_upper": 862.14,
    "bb_lower": 612.98,
    "price_vs_sma20_pct": -10.78,
    "price_vs_sma50_pct": -13.85,
    "volume_ratio": 1.03
  },
  "fundamentals": {
    "market_cap": 891965538304,
    "pe_ratio": 48.750122,
    "forward_pe": 43.90953,
    "price_to_book": 37.461975,
    "price_to_sales": 15.011251,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.52,
    "pct_from_52w_low": 59.51
  },
  "macro": {
    "spy": {
      "price": 643.11,
      "change_1d_pct": 0.34,
      "change_7d_pct": 2.69
    },
    "vix": {
      "level": 14.49,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.24
    },
    "dollar_index": {
      "level": 97.84
    },
    "gold": {
      "price": 3358.7
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Jim Cramer on Eli Lilly Stock: \u201cIt Just Got Pole-Axed, Laid to Waste\u201d",
      "source": "Yahoo",
      "datetime": 1755113844,
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer commented on. Cramer highlighted the reasons behind the stock\u2019s decline recently. He remarked: \u201cLast and least, I look at the drug stocks and I can\u2019t believe how awful they really are, with now Eli Lilly last joining the ugly fray with",
      "url": "https://finnhub.io/api/news?id=697e30f6d9f64b542f00d0ccad648a69564c6f0cffae57b3025844890f67f740"
    },
    {
      "headline": "Why Eli Lilly Stock Popped Today",
      "source": "Yahoo",
      "datetime": 1755112801,
      "summary": "The GLP-1 weight loss wars have gone global.",
      "url": "https://finnhub.io/api/news?id=a80d4c440efe8dab946cf8c5273083398a734339baf6e2402881f560585366a4"
    },
    {
      "headline": "Eli Lilly (LLY) Stock Trades Up, Here Is Why",
      "source": "Yahoo",
      "datetime": 1755111667,
      "summary": "Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock rebounding from a recent selloff.",
      "url": "https://finnhub.io/api/news?id=4dbb3d9754047a7336ad5131d8bf7a0fcb55b4f57ea487e7cea38ec7533a44d1"
    },
    {
      "headline": "Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst",
      "source": "Yahoo",
      "datetime": 1755109835,
      "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly\u2019s recent setback a",
      "url": "https://finnhub.io/api/news?id=bb356bc0f2e26b577849709486af2f1e51e794395e0017077eaee12c46315070"
    },
    {
      "headline": "3 Unusual Insider Transactions you Should Know About",
      "source": "Yahoo",
      "datetime": 1755108960,
      "summary": "While no single indicator can guarantee a stock's performance, the pattern of insider transactions can provide a powerful glimpse into a company's prospects.",
      "url": "https://finnhub.io/api/news?id=24f96c3beab2dcc2a3d7592bdb7dad5478de5732d041085aea20979b44bf3794"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-08-13",
      "description": "xslF345X05/wk-form4_1755116139.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000218/xslF345X05/wk-form4_1755116139.xml"
    },
    {
      "form": "4",
      "date": "2025-08-12",
      "description": "xslF345X05/wk-form4_1755030182.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000216/xslF345X05/wk-form4_1755030182.xml"
    },
    {
      "form": "4",
      "date": "2025-08-12",
      "description": "xslF345X05/wk-form4_1755030049.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000214/xslF345X05/wk-form4_1755030049.xml"
    },
    {
      "form": "4",
      "date": "2025-08-12",
      "description": "xslF345X05/wk-form4_1755029946.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000212/xslF345X05/wk-form4_1755029946.xml"
    },
    {
      "form": "4",
      "date": "2025-08-12",
      "description": "xslF345X05/wk-form4_1755029865.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000210/xslF345X05/wk-form4_1755029865.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}